Author

Birgitta Dietz

Observed institutions: Abbott (Germany), AbbVie (Germany)

OpenAlex ID: A5113715360

Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV

2009 · Kit N. Simpson, Alvin Strassburger, et al. · PharmacoEconomics · 69

Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.

2007 · Thomas Mittendorf, Birgitta Dietz, et al. · PubMed · 34

Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy

2008 · Rukmini Rajagopalan, David Laitinen, et al. · AIDS Care · 29

Cost Effectiveness of Lopinavir/Ritonavir Tablets Compared with Atazanavir plus Ritonavir in Antiretroviral-Experienced Patients in the UK, France, Italy and Spain

2007 · Kit N Simpson, Walter J Jones, et al. · Clinical Drug Investigation · 24

Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States

2013 · Kit N. Simpson, Pamela P. Pei, et al. · PharmacoEconomics · 23

Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument

2013 · Roger T. Anderson, Robert W. Baran, et al. · Quality of Life Research · 21

Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial

2013 · Roger T. Anderson, Robert W. Baran, et al. · Quality of Life Research · 19

Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study

2009 · Kit N. Simpson, Rukmini Rajagopalan, et al. · Advances in Therapy · 16

Cost Effectiveness of Lopinavir/Ritonavir Compared with Atazanavir??plus Ritonavir in Antiretroviral-Experienced Patients in??the US

2007 · Kit N Simpson, Walter J Jones, et al. · Clinical Drug Investigation · 11

Economics of Switching to Second-Line Antiretroviral Therapy with Lopinavir/Ritonavir in Africa: Estimates Based on DART Trial Results and Costs for Uganda and Kenya

2011 · Kit N. Simpson, Robert W. Baran, et al. · Value in Health · 8

Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data

2011 · Kit N Simpson, Birgitta Dietz, et al. · Cost Effectiveness and Resource Allocation · 7

Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.

2008 · Lynda C Doward, Birgitta Dietz, et al. · PubMed · 4

Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age

2013 · Jörgen Möller, Kamal Desai, et al. · Journal of Medical Economics · 1

Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy

2010 · John Hornberger, Kit Simpson, et al. · Advances in Therapy · 1

Su1057 Patient Reported Outcomes (Pros) in French HCV-Infected Patients Treated With Direct Acting Antivirals (DAAs) ± Ribavirin (RBV): Response and Psychometric Evaluation of the HCV-PRO

2014 · Roger T. Anderson, Robert W. Baran, et al. · Gastroenterology

Hepatitis C Virus-Patient-Reported Outcomes Instrument

2014 · Roger T. Anderson, Robert W. Baran, et al. · PsycTESTS Dataset

Sa1051 Developing the Chronic Hepatitis C Virus Treatment Sastisfaction (HCVTSAT) Instrument

2012 · Sheryl Szeinbach, Robert Baran, et al. · Gastroenterology

Works count: 19

Citation count: 267

H-index: 9

I10-index: 9